TTRX
Turn Therapeutics
Stock NASDAQ – Stock Market Prices, News & Analysis
Biopharmaceutical company developing innovative immuno-oncology therapies to treat various cancers.
Turn Therapeutics
TTRX
Biopharmaceutical company developing innovative immuno-oncology therapies to treat various cancers.
Price history of Turn Therapeutics
Price history of Turn Therapeutics
Performance & Momentum
Strategic Analysis
Turn Therapeutics • 2026
Turn Therapeutics is positioning itself as an innovative player in immuno-oncology, developing targeted biopharmaceutical treatments for various cancers. Its value proposition is based on advances in clinical research aimed at transforming existing therapeutic options in a sector with high medical and commercial stakes.
- Advanced expertise in immunotherapy and oncology, two high-growth segments
- Strong focus on clinical research and innovative medicines
- Addresses unmet medical needs in cancer treatment
- Weak and persistent stock performance over several years, reflecting operational challenges or clinical validation hurdles
- Lack of short-term growth drivers and neutral momentum, signaling an uncertain environment
Momentum is currently neutral with a pronounced negative trend over the medium term, indicating significant pressure on the stock. This calls for heightened caution among investors, who are awaiting clear progress in research or clinical catalysts that could reinvigorate the share price trajectory.
Similar stocks to Turn Therapeutics
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
